Combination therapy using sympathetic nervous system antagonists and endothelin antagonists

Abstract

Methods are provided for preventing or inhibiting adverse cardiovascular effects associated with administration of a sympathetic nervous system antagonist in a subject, in which a subject in need thereof is administered a sympathetic nervous system antagonist and an endothelin antagonist. Methods for improving the efficacy of a sympathetic nervous system antagonist are also provided, comprising administering to a subject in need thereof a sympathetic nervous system antagonist together with an endothelin antagonist. Methods of treating prostate cancer or benign prostate hyperplasia (BPH) in a subject are also provided, in which a subject in need thereof is administered a sympathetic nervous system antagonist and an endothelin antagonist. The sympathetic nervous system antagonist may be an alpha-adrenoceptor antagonist, a ganglionic blocking agent or another inhibitor of the actions of the sympathetic nervous system.

Dependencies are inferred from the claim text.